Chronic hepatitis B viral (HBV) infection remains a significant global health problem.
Evidence‐based guidelines are needed to help providers determine when treatment should …

Chronic hepatitis B (CHB) remains the leading cause of liver-related morbidity and mortality
across the world. If left untreated, approximately one-third of these patients will progress to …

Background: Vaccination, screening, and linkage to care can reduce the burden of chronic
hepatitis B virus (HBV) infection. However, recommendations vary among organizations …

Hepatocellular carcinoma (HCC) is a complex disease that is dually challenging to treat due
to underlying chronic liver disease in addition to the cancer itself. The prognosis of patients …

This review analyzes progress and limitations of diagnosis, screening, and therapy of
patients with chronic hepatitis B infection. A literature review was carried out by framing the …

Chronic hepatitis B virus (HBV) infection is a dynamic state of interactions between HBV, the
hepatocytes, and the immune system of the host. Patients with an extended immune …

Background & Aims Chronic infection with hepatitis B virus (HBV) causes liver disease and
cirrhosis. It is not clear how treatment of chronic HBV infection affects patient-reported …

Chronic infections with the hepatitis B and C viruses have significant worldwide health and
economic impacts. Previous treatments for hepatitis C such as interferon and ribavirin …

Abstract Background & Aims Several studies suggested that efficacy of tenofovir in reducing
the risk of the development of hepatocellular carcinoma (HCC) might be better than that of …

Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide, with 75% of
those affected distributed in the Asia-Pacific region. Approximately one million HBV-infected …